Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens.
Antimicrobial synergy resulting from combined antibiotic therapy is often important in the treatment of serious bacterial infections. To investigate the interactions between cefotaxime (CTX), desacetylcefotaxime (DES), and ofloxacin (OFL), 247 recent clinical isolates were tested for in vitro susceptibility to each antibiotic alone by an agar dilution technique and retested with the various antibiotic combinations using a checkerboard protocol. Fractional inhibitory concentrations were calculated for all organisms with all drug combinations. Time kill kinetic studies were performed on selected isolates to examine the bactericidal activity of the various antimicrobial combinations. Of the 110 gram-negative organisms tested, synergy or partial synergy between CTX, DES and OFL was demonstrable for 89 (81%). Included in the study were 70 members of the Enterobacteriaceae family, 20 isolates of Pseudomonas aeruginosa, 10 strains of Acinetobacter baumannii, and 10 isolates of Xanthomonas maltophilia. Additive activity was observed against an additional 13 (11%) isolates. Findings were similar for the 89 gram-positive isolates examined. Organisms tested included methicillin-resistant Staphylococcus aureus (20), methicillin-susceptible Staphylococcus aureus (20), methicillin-resistant Staphylococcus epidermidis (9), methicillin-susceptible S. epidermidis (10), Enterococcus faecalis (10), and Streptococcus pneumoniae (20). Synergy or partial synergy was observed against 81 (91%). Less synergistic activity was detected, however, with members of the Bacteroides fragilis group. Of the 48 organisms tested, synergy or partial synergy was noted for only 27 (57%). Isolates representative of each major group of organisms included in the study were tested to determine whether synergistic bactericidal activity was also demonstrable with the three drugs. Time kill studies supported the checkerboard results.(ABSTRACT TRUNCATED AT 250 WORDS)
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004338:Drug Combinations; D004351:Drug Resistance; D004357:Drug Synergism; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*
D000890:Anti-Infective Agents; D002511:Cephalosporins; D004338:Drug Combinations; C029281:desacetylcefotaxime; D015242:Ofloxacin; D002439:Cefotaxime